RE:RE:RE:Additions to Study DesignOnce Ruvidar PDT is approved Theralase will be able to point to it's superior efficacy immediately and it's superior durable response will emerge more and more over time as Ruvidar maintains it's CR rate while Adstliladrin (for example) declines. With safety and only one or two treatments required Ruvidar will become the obvious choice.
Eoganacht wrote: I think this is good. The trial still ends at 450 days past initial response, but Theralase will continue to compile durable response data. I don't think any prospective treatment we've heard about so far will be able to compete with Ruvidar PDT's durable response and Theralase will have the data to prove it.
Oilminerdeluxe wrote: Ungodly frustrating. But what can you do? Hope we get a nice update whenever it arrives.